Did nothing for price | OPK Message Board Posts

OPKO Health, Inc.

  OPK website

OPK   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  2202 of 2223  at  10/21/2019 8:47:25 AM  by

E_K_S


Opko Health up 11% premarket on positive somatrogon data

|About: OPKO Health, Inc. (OPK)|By:, SA News Editor
 

OPKO Health (NASDAQ:OPK) and licensee Pfizer (NYSE:PFE) announce successful results from a Phase 3 clinical trial evaluating once-weekly somatrogon in 224 pre-pubertal children with growth hormone deficiency.

The study met the primary endpoint of non-inferiority (no worse than) to daily Genotropin (somatropin) as measured by annual height velocity at month 12.

Under their 2014 agreement, OPKO is responsible for conducting clinical trials while Pfizer is responsible for regulatory submissions and commercialization.

OPK is up 11% premarket on robust volume. PFE is up a fraction.

-----------------------------------------------------------
 
FWIW, I see that OPK is selling 25% BELOW it's net Tangible Asset value per share. 
 
EKS 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 67
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...